GSK, Pfizer RSV vaccine sales fall in US
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer as the pharmaceutical giant grapples with a downturn in demand for COVID-19 vaccines and treatments.
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV vaccine. The ruling is part of ongoing litigation between the two drugmakers over their respective RSV vaccines.
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
FiercePharma4h
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
ENDPOINTS NEWS47m
GSK's RSV vac­cine Arexvy shows long-term pro­tec­tion in Phase 3 tri­al
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
GSK rises Monday, outperforms market
Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
GSK, Sanofi and CSL will also make additional bulk vaccine ingredients matched to circulating strains of bird flu, Boucher ...
BioSpace1d
TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO
After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...
The Valdosta Daily Times9h
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E adjuvant.
FiercePharma1d
In long-acting HIV PrEP access showdown with Gilead, GSK moves to triple Apretude supply for certain countries
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...